Skip to main content

Table 3 Subgroup analyses of MPR and pCR

From: Neoadjuvant PD-1 blockade combined with chemotherapy is not superior to neoadjuvant chemotherapy alone in resectable locally advanced esophageal carcinoma

 

MPR (n=65)

pCR (n=65)

 

Yes (n=17)

No (n=48)

P value

YES (n=7)

NO (n=58)

P value

TRG (grade)

  

< 0.001

  

< 0.001

 0

7 (100.0%)

0 (0.0%)

 

7 (100.0%)

0 (0.0%)

 

 1

10 (100.0%)

0 (0.0%)

 

0 (0.0%)

10 (100.0%)

 

 2

0 (0.0%)

11 (100.0%)

 

0 (0.0%)

11 (100.0%)

 

 3

0 (0.0%)

37 (100.0%)

 

0 (0.0%)

37 (100.0%)

 

TNM stage of tumor

  

< 0.001

  

0.010

 Down

15 (51.7%)

14 (48.3%)

 

7 (24.1%)

22 (75.9%)

 

 UP

2 (11.1%)

16 (88.9%)

 

0 (0.0%)

18 (100.0%)

 

 Stable

0 (0.0%)

18 (100.0%)

 

0 (0.0%)

18 (100.0%)

 
  1. nICT neoadjuvant immunochemotherapy, nCT neoadjuvant chemotherapy, pCR pathological complete remission, MPR major pathological response, TRG tumor regression grade